PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid CMB control number. Complete if Known		
				Application Number	10/568,572	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	August 14, 2006 (371(c) Date)	
				First Named Inventor	Heidi Lopez de Diego, et al.	
				Art Unit	1624	
				Examiner Name	Emily B. Bernhardt	
Sheet	2	of	2	Attorney Docket Number	453-US-PCT	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), t		T ²					
/E.B./		HALEBLIAN, JOHN, et al., "Pharmaceutical Applications of Polymorphism", Journal of Pharmaceutical Sciences, August 1969, pp. 911-929, Vol. 58, No. 8.						
/E.B./	/E.B./ DAVIES, Huw M. L., et al., "Asymmetric Synthesis of (+)-Indatraline Using Rhodium-Cataly. C-H Activation", Tetrahedron Letters, 2002, pp. 4951-4953, 43, Pergamon.							
	_							

Examiner	//*** '1	Date	00/40/0000
Signature	/Emily Bernhardt/	Consider	ed 05/10/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.